TFO
AKRO

Tarbox Family Office’s Akero Therapeutics AKRO Stock Holding History

Tarbox Family Office’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-39
Closed -$1K – 1142
2021
Q1 		$1K Hold
39
– – ﹤0.01% 987
2020
Q4 		$1K Hold
39
– – ﹤0.01% 951
2020
Q3 		$1K Hold
39
– – ﹤0.01% 900
2020
Q2 		$1K Buy
+39
New +$891 ﹤0.01% 892

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
YCM
Yiheng Capital Management San Francisco, California $231M AUM 29.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Tarbox Family Office's AKRO Position: Q2 2021 in Review

Tarbox Family Office sold out of Akero Therapeutics (AKRO) in Q2 2021, closing a stake of 39 shares — an estimated $1K sold.

Tarbox Family Office first reported a position in AKRO in Q2 2020 and held it in 4 quarters. The position peaked at $1K in Q1 2021. 97 funds tracked by Wall St. Rank hold AKRO as of Q2 2021.

  • Tarbox Family Office reported no remaining Akero Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Tarbox Family Office sold 39 Akero Therapeutics shares in Q2 2021, an estimated $1K.
  • Tarbox Family Office first reported a position in Akero Therapeutics in Q2 2020 and held it in 4 quarters.
  • Tarbox Family Office's Akero Therapeutics position peaked at $1K in Q1 2021.
  • 97 funds tracked by Wall St. Rank held Akero Therapeutics as of Q2 2021.

Based on Tarbox Family Office's 13F filing for Q2 2021, filed 16 Jul 2021.